Bioxytran (BIXT) Cash from Operations (2010 - 2026)
Bioxytran (BIXT) posted Cash from Operations of 238610.0 for Q1 2026, down 0.69% sequentially from 236971.0 in Q4 2025, and down 42.6% YoY from 415728.9 in Q1 2025.
Bioxytran (BIXT) Cash from Operations (2010 - 2026) Analysis & Trends
Bioxytran has reported Cash from Operations for 17 years, with the latest figure at 238610.0 in Q1 2026.
- Quarterly Cash from Operations fell 42.6% year-over-year to 238610.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 597742.0 (down 36.14% YoY) and the FY2025 annual result came in at 526455.0, down 38.06% from the prior year.
- Cash from Operations eased to 238610.0 in Q1 2026 per BIXT's latest filing, from 236971.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 41474.0 in Q3 2025 and troughed at 718774.0 in Q3 2022.
- A 5-year average of 219142.71 and a median of 154693.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations plunged 398.98% in 2022, then surged 78.53% in 2024.
- Over 5 years, Cash from Operations stood at 154693.0 in 2022, then surged by 40.12% to 92626.0 in 2023, then sank by 38.12% to 127937.0 in 2024, then slumped by 85.22% to 236971.0 in 2025, then slipped by 0.69% to 238610.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 238610.0, 236971.0, and 41474.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - | -349,773.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -238,610.00 |
| Mar 31, 2026 | -238,610.00 |
| Dec 31, 2025 | -236,971.00 |
| Dec 31, 2025 | -236,971.00 |
| Sep 30, 2025 | -41,474.00 |
| Sep 30, 2025 | -41,474.00 |
| Jun 30, 2025 | -80,687.00 |
| Jun 30, 2025 | -80,687.00 |
| Mar 31, 2025 | -167,323.00 |
| Mar 31, 2025 | -167,323.00 |
| Dec 31, 2024 | -127,937.00 |
| Dec 31, 2024 | -127,937.00 |
| Sep 30, 2024 | -73,547.00 |
| Sep 30, 2024 | -73,547.00 |
| Jun 30, 2024 | -70,265.00 |
| Jun 30, 2024 | -70,265.00 |
| Mar 31, 2024 | -109,567.00 |
| Mar 31, 2024 | -109,567.00 |
| Dec 31, 2023 | -92,626.00 |
| Dec 31, 2023 | -92,626.00 |